Vera Therapeutics VERA Cash Flow Statement (2020-2026)

NASDAQ VERA
$35.90 +0.91 (+2.62%)
As of: Sep 4, 2026 · 2:22 PM EDT
Reported Financials

Vera Therapeutics Quarterly Cash Flow Statement

Periods 26 quarters
Latest Jun 2026

Vera Therapeutics reported cash from operations of -$100.25M and free cash flow of -$100.25M for the quarter ended Jun 2026, down 83.0% year over year. This cash flow statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-7.25M-16.60M-17.11M-14.92M-24.82M-33.29M-30.51M-20.64M-20.54M-26.12M-28.83M-34.15M-46.98M-44.12M-52.08M-75.69M-80.16M-90.59M-120.60M-108.99M
Share-based Compensation
2.89M0.96M3.49M3.80M3.77M2.75M5.65M5.85M5.73M3.22M6.48M6.25M6.49M6.22M7.74M9.47M9.74M10.96M13.21M15.86M
Gains from Investment Securities
0.01M0.14M0.13M
Cash from Operations
-5.48M-6.44M-8.98M-19.03M-18.42M-21.16M-26.29M-17.77M-22.97M-25.14M-33.83M-24.78M-36.88M-39.18M-54.41M-54.80M-61.91M-69.99M-106.50M-100.25M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles
0.56M0.55M0.56M0.59M0.58M0.56M0.55M0.53M0.52M0.50M0.50M0.55M0.46M0.44M0.43M0.11M0.12M0.12M
Depreciation & Amortization (CF)Depreciation & Amortization
0.01M0.00M0.01M0.01M0.02M0.06M0.09M0.12M0.13M0.14M0.14M0.13M
Change in Working Capital
Change in Account Payables
-0.76M0.42M5.94M-0.24M-0.07M4.98M-6.67M7.95M-0.98M-1.18M-5.91M-0.55M-0.06M3.06M1.60M3.90M4.79M3.62M-7.97M0.66M
Change in Accured Expenses
1.02M3.22M4.22M-2.41M0.47M4.75M4.64M-4.61M-1.19M-1.05M-1.69M4.58M8.07M-3.77M-4.78M8.10M3.92M7.21M-0.44M2.51M
Other Working Capital Changes
-0.63M-0.71M3.94M3.60M0.15M0.48M-3.75M2.30M-0.55M-0.65M-0.64M-1.69M0.45M-0.53M5.88M-1.71M-0.61M0.37M5.14M9.43M
Investing Activities
Capital Expenditures
5.00M0.02M0.01M0.04M0.06M0.09M0.24M0.65M0.19M0.21M0.13M0.10M0.02M
Change in Acquisitions & Divestments
16.00M38.00M24.00M36.90M22.40M44.90M71.82M31.68M58.50M111.50M73.28M106.25M126.06M168.59M105.27M87.92M131.03M
Cash from Investing Activities
-5.00M-39.45M-42.09M-2.44M13.44M12.23M-86.45M16.23M18.56M-219.29M-22.68M38.32M-221.38M15.32M28.54M69.76M80.66M-137.82M32.86M
Financing Activities
Other financing activities
0.23M0.05M0.97M0.83M0.24M0.43M0.30M0.09M6.91M3.44M0.75M2.31M1.53M0.46M0.80M4.19M3.94M1.92M
Debt Issuance and Repayment
Long-Term Debt Issuances
Change in Capital Stock
Net Shares Issued and Repurchased
0.15M0.02M0.01M0.20M0.41M0.00M0.04M0.05M0.11M0.71M0.36M0.10M1.49M0.10M0.05M0.00M2.31M0.16M0.17M
Net Equity Issued and Repurchased
-51.18M86.13M
Misc.
Cash from Financing Activities
4.92M80.27M0.05M0.91M20.71M107.98M0.43M0.30M24.83M276.54M3.44M0.74M325.95M1.53M20.29M0.80M286.28M3.94M1.92M
Change in Cash
-5.48M-6.52M31.83M-61.08M-19.95M12.98M93.93M-103.79M-6.45M18.24M23.42M-44.02M2.17M65.39M-37.56M-5.97M8.65M296.95M-240.37M-65.47M
Free Cash Flow
-5.48M-11.44M-9.00M-19.04M-18.46M-21.16M-26.29M-17.77M-22.97M-25.21M-33.83M-24.87M-37.12M-39.83M-54.59M-55.01M-62.04M-70.10M-106.52M-100.25M
Net Cash Flow
-5.48M-6.52M31.83M-61.08M-19.95M12.98M93.93M-103.79M-6.45M18.24M23.42M-44.02M2.17M65.39M-37.56M-5.97M8.65M296.95M-240.37M-65.47M